Actavis Generics Company Intelligence Report

Date: January 22, 2011
Pages: 18
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A2ED474986DEN
Leaflet:

Download PDF Leaflet

Actavis Generics Company Intelligence Report
Actavis, originally named Pharmaco, was created in 1956; in May 2004 it changed itsname to Actavis. The company is headquartered in Iceland, but has manufacturing operations in 14 countries. Actavis employs around 10,000 members of staff operating in some 40 countries.

The company is particularly active in Eastern Europe, such as Bulgaria, Russia, and Serbia, but in recent years has been pushing for a stronger presence in the EU, and in the United States. The company gained its first US ANDA approvals in August 2005, through its Amide subsidiary.

In August 2007, Actavis was taken over by Novator, an investment group which included members of Actavis’ Board. With the takeover complete, Actavis became a private company, with its shares delisted from the Icelandic stock exchange. Actavis had a difficult year in the US in 2008, with product recalls being initiated from its Actavis South Atlantic and Actavis Totowa units. These led to congressional attention.

Actavis has been restructuring in 2010. In February 2010, the firm announced plans to expand its manufacturing site in Iceland, creating 50 new jobs, and plans to divest its
Norwegian plasters, athletic tape and adhesive coatings business. This was followed in March with news that the firm was divesting its Bulgarian distribution business, and in April Actavis announced plans to consolidate its New Jersey manufacturing operations, with the loss of some jobs. In May, the firm announced it had established a regional office for China in Beijing.

In July 2010, Actavis reported that it had successfully agreed a debt refinancing arrangement in collaboration with its lenders. The move should end the uncertainty that Actavis has faced since the global economic crisis began, and speculation that the firm may have had to be sold. On 22nd September 2010, the EC reported it had approved the proposed acquisition by Deutsche Bank of control over Actavis.

In September 2010, Actavis announced plans to enter the field of biosimilars. The move came through an initial agreement with Bioton for Actavis to acquire 51% of Bioton's shares in Biopartners Holdings.


EXECUTIVE SUMMARY

INTRODUCTION

PRODUCTS

Manufacturing sites
Actavis, ANDA Approvals January 2006 – September 2010
Recent product approvals
Mycophenolate mofetil (EU)
Zolpidem tartrate (US)
Topotecan (EU)
Losartan (US)
Bupropion (US)
Valaciclovir (Switzerland)
Telmisartan (EU)
Tamsulosin (US)
Alprazolam (US)
Lercanidipine (Europe)
Losartan (Switzerland)
Valaciclovir (France)
Atorvastatin (Spain)
Topiramate (UK, Germany, France, Switzerland)
Lisinopril, ramipril and fluvastatin (Ireland)
Irinotecan (UK, France, Netherlands, Germany, Austria, Sweden)

FINANCIAL RESULTS

Actavis: fiscal year results, in euro millions
Actavis: fiscal year results, in US$ millions
Actavis: total revenues by division, in euro millions and US$ millions
Actavis: total revenues by region, in euro millions and US$ millions

MAJOR DEVELOPMENTS

EC clears acquisition of control of Actavis by Deutsche Bank
Actavis opens Beijing office
Actavis to consolidate its New Jersey manufacturing operations
Actavis divests its Bulgarian distribution business
Actavis to expand manufacturing site in Iceland
Actavis divests Norgesplaster
Mergers, acquisitions and agreements
Actavis plans biosimilars entry with help from Biopartners acquisition
Sagent and Actavis enter into US development, supply and marketing agreement
Actavis enters co-development relationship with Bioluz
Litigation
Shire gains lisdexamphetamine exclusivity victory
Actavis challenges Labopharm's US trazodone patents
Eli Lilly receives atomoxetine patent setback
Shire widens guanfacine lawsuits to include Actavis
Penwest and Endo settle oxymorphone patent litigation with Barr
sanofi-aventis enters series of oxaliplatin patent settlements

CONTACT DETAILS
Skip to top


Ranbaxy Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 24 pages
Apotex Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 20 pages
Hospira Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 18 pages

Ask Your Question

Actavis Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: